TwentyTwentyTweets
- Sorry to have missed you! Would love to know what difference your approach has made to QoL for someone with… twitter.com/i/web/status/1… 3 hours ago
- And again - think before you click - and then buy locally instead. #BeKind Delivery disaster: the hidden environmen… twitter.com/i/web/status/1… 1 week ago
- How about we all return to forward planning, buying local and/or direct from supplier? #BeKind Concerns over safety… twitter.com/i/web/status/1… 1 week ago
-
Recent Posts
Pages
Tag Archives: VBP
Guest Blogspot: Negotiations with the UK Government over pharmaceutical pricing have achieved a good result for patients, the NHS and the industry.
The UK Government and the pharmaceutical industry shared many objectives throughout the recent drug pricing negotiations. For example, there was always broad agreement that: The total future drug bill needed to be affordable in the context of other spending in … Continue reading
Posted in Andrew Lansley, Business, Cancer, Department of Health, Drugs, Innovation, Jeremy Hunt, NHS, Patients, Pharma, Research, Smoking ban
Tagged 2020health, Andrew Lansley, Department of Health, Drugs, government, innovation, Jeremy Hunt, National Health Service, NHS, NICE, parallel export, parallel imporrt, patient, Patient Access Scheme, Patients, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing, VBP
1 Comment
Guest Blogspot: Think carefully about value-based drug pricing in the UK and let common sense prevail.
David Cameron and Jeremy Hunt share an important skill. They both have firsts from Oxford in Politics, Philosophy and Economics (PPE). I am not the greatest fan of this course because I would like to see more scientists, engineers and … Continue reading
Posted in Business, competition, David Cameron, Department of Health, Drugs, Election, Jeremy Hunt, NHS, Patients, Pharma, Policy, Primary Care
Tagged 2020health, block-buster, competition, David Cameron, demand, Department of Health, drug pricing system, Drugs, elderly, GP, GPs, Health Bill, innovation, medicine, National Health Service, NHS, NICE, parallel exports, parallel imports, patient, Patients, pharmaceutical, Philosophy and Economics, Politics, PPE, PPRS, pricing, quality of life, R&D, reference price, Research, value-based, value-based pricing, VBP
Leave a comment
Branded vs. generic debate continues
The debate around cutting costs had taken a view that by swapping branded drugs for generics will somehow help the NHS make £20 billion of savings, is disproportionate and ill informed. In a really interesting survey carried out by the … Continue reading
